Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)

Orlowski, R (author)

Facon, T (author)

Kumar, S (author)

show more...

Plesner, T (author)

Moreau, P (author)

Bahlis, N (author)

Basu, S (author)

Nahi, H (author)

Karolinska Institutet

Hulin, C (author)

Quach, H (author)

Goldschmidt, H (author)

O'Dwyer, M (author)

Perrot, A (author)

Venner, C (author)

Weisel, K (author)

Mace, J (author)

Raje, N (author)

Tiab, M (author)

Macro, M (author)

Frenzel, L (author)

Leleu, X (author)

Ahmadi, T (author)

Wang, JP (author)

Van Rampelbergh, R (author)

Uhlar, C (author)

Tromp, B (author)

Delioukina, M (author)

Vermeulen, J (author)

Usmani, S (author)

show less...

 (creator_code:org_t)

2021

2021

English.

In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. - 2152-2650. ; 21, s. S424-S425

Related links:

http://kipublication...

• Conference paper (other academic/artistic)